Peer-reviewed veterinary case report
Inhaled steroids for treating chronic cough in dogs
By Chan, Jennifer C & Johnson, Lynelle R·Published in Journal of veterinary internal medicine·2023·William R. Pritchard Veterinary Medical Teaching Hospital, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prospective evaluation of the efficacy of inhaled steroids administered via the AeroDawg spacing chamber in management of dogs with chronic cough.
- Species:
- dog
Plain-English summary
A group of 36 dogs with chronic cough due to inflammatory airway disease or airway collapse were treated with an inhaled steroid called fluticasone propionate. Over six weeks, the dogs showed significant improvements in their cough frequency and severity, and their quality of life scores improved dramatically. Most dogs adapted well to the inhaler, with only one dog having trouble accepting the treatment. This suggests that inhaled steroids can be an effective way to manage cough in dogs with these conditions.
People also search for: dog chronic cough treatment · inhaled steroids for dogs · fluticasone propionate for dogs cough
Abstract
BACKGROUND: Glucocorticoids are frequently required for management of cough because of inflammatory airway disease (IAD) and airway collapse (AWC). OBJECTIVES/HYPOTHESIS: To determine the efficacy and feasibility of inhaled administration of corticosteroids in controlling cough in dogs with noninfectious airway disease. ANIMALS: Thirty-six client-owned dogs. METHODS: Dogs were prospectively recruited for this placebo-controlled cross-over study. Inflammatory airway disease was diagnosed through bronchoalveolar lavage cytology. Airway collapse was diagnosed through bronchoscopy, or if dogs were unsuitable anesthetic candidates, by crackles on auscultation, radiographic changes in airway diameter, or fluoroscopy. Dogs were randomly assigned to receive placebo or fluticasone propionate for the first 2 weeks of the trial then crossed over to fluticasone. A quality of life (QOL) survey (best score 0, worst score 85) was completed at 0 and 6 weeks. A visual-analog cough survey was submitted at 0, 2, 4, and 6 weeks to assess cough, feasibility, and adverse effects of treatment. RESULTS: For 32 dogs, QOL score at study end (mean 11.3 ± 9.7) was significantly lower (P < .0001) compared to entry (mean 28.1 ± 14.1), with a median change of 69% in QOL score, indicating improved quality of life. Cough frequency, duration, and severity were significantly (P < .0001) decreased at study end. Feasibility of aerosolized delivery improved with continued use (P = .05) with only 1 dog unable to accept inhaled medication. CONCLUSION AND CLINICAL IMPORTANCE: This study supports the utility of fluticasone propionate by inhalation in management of cough in dogs with IAD and AWC.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36892108/